In vitro/in vivo studies on the improvement of the dissolution rate and anti-inflammatory effect of meloxicam using solvent deposition technique;Études in vitro/in vivo de l'amélioration du taux de dissolution et de l'effet anti-inflammatoire du meloxicam à l'aide de la technique de précipitation par les solvants

S.T.P. Pharma Pratiques

Volumn 18, Issue 3, 2008, Pages 275-284

  Hassan, Maha A ^a  

^a Assiut University   (Egypt)

Author keywords

Anti inflammatory effect; Dissolution; Galenic development; Meloxicam; Pharmaceutical technology

Indexed keywords

MELOXICAM; MICROCRYSTALLINE CELLULOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADSORPTION; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PAW EDEMA; RAT; STATISTICAL ANALYSIS; SYSTEM ANALYSIS; TECHNIQUE; WETTABILITY;

EID: 47149086978     PISSN: 11571497     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sternon J, Appelboom T. - Meloxicam. - Rev Med Brux., 19 (1): 29-32 (1998).
2. Ogino K, Hatanaka KO, Kawamura M, Ohno T, Harada Y. - Meloxicam inhibits prostaglandin E2 generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. - Pharmacology, 61: 244-50 (2000).
3. Noble S, Balfour JA. - Meloxicam. - Drugs, 51 (3): 424-32 (1996).
4. Ahmed M, Khanna D, Furst DE. - Meloxicam in rheumatoid arthritis. - Expert Opin Drug Metab Toxicol., 1 (4): 739-51 (2005).
5. Fleischmann R, Igbal I, Slobodin G. - Meloxicam. - Expert Opin Pharmacother., 3 (10): 1501-12 (2002).
6. Donnelly MT, Hawkey CJ. - COX-II inhibitors, a new generation of safer NSAIDs? - Aliment Pharmacol Ther., 11: 227-36 (1997).
7. Trummlitz G, Engelhardt G, Busch U. - Meloxicam. - Drugs of Future, 14: 1047-8 (1989).
8. Patoia L, Santucci L, Furno P, et al. - A 4-week double blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. - Br J Rheum., 35: S161-7 (1996).
9. Wotjulewski JA, Schattenkirchner M, Barcelo P, et al. - A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. - Br J Rheum., 35: S122-8 (1996).
10. Stei P, Kruss B, Wiegleb J, Trach V. - Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. - Br J Rheumatol., 35: Suppl. 1: 44-50 (1996).
11. Cetin EO, Buduneli N, Atlihan E, Kirilmaz L. - In-vitro studies of a degradable device for controlled release of meloxicam. - J Clin Periodontol., 32 (7): 773-7 (2005).
12. Cetin EO, Buduneli N, Atlihan E, Kirilmaz L. - In-vitro studies on controlled-release cellulose acetate films for local delivery of chlorhexidine, indomethacin, and meloxicam. - J Clin Periodontol., 31 (12): 1117-21 (2004).
13. Vijaya Kumar SG, Mishra DN. - Preparation, characterization and in-vitro dissolution studies of solid dispersion of meloxicam with PEG6000. - Yakugaku Zasshi., 126 (8): 657-64 (2006).
14. Johansen H, Moller N. - Solvent deposition method for enhancement of dissolution rate: Importance of drug-to-excipient ratio. - J Pharm Sci., 67 (1): 134-36 (1978).
15. Vijaya Kumar SG, Mishra DN. - Preparation, characterization and in-vitro dissolution studies of solid systems of valdecoxib with chitosan. - Chem Pharm Bull., 54 (8): 1102-6 (2006).
16. Barzegar-Jalali M, Maleki N, Garjani A, Khandar AA, Haji-Hosseinloo M, Jabbari R, Dastmalchi S. - Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. - Drug Dev Ind Pharm., 28 (6): 681-686 (2002).